121 related articles for article (PubMed ID: 18824308)
1. [Testing of a new probe 16/18/45 Hybrid Capture (Digene) in women with high risk HPV infection].
Hantz S; Decroisette E; Caly H; Renaudie J; Dussartre C; Bakeland D; Denis F; Alain S
Pathol Biol (Paris); 2009 Feb; 57(1):81-5. PubMed ID: 18824308
[TBL] [Abstract][Full Text] [Related]
2. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
3. High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products.
Geraets DT; Heideman DA; de Koning MN; Snijders PJ; Meijer CJ; van Doorn LJ; Quint WG
J Clin Virol; 2009 Nov; 46 Suppl 3():S16-20. PubMed ID: 20129069
[TBL] [Abstract][Full Text] [Related]
4. [HPV detection and typing by INNO-LiPA assay on liquid cytology media Easyfix Labonord after extraction QIAamp DNA Blood Mini Kit Qiagen and Nuclisens easyMAG Biomérieux].
Hantz S; Goudard M; Marczuk V; Renaudie J; Dussartre C; Bakeland D; Denis F; Alain S
Pathol Biol (Paris); 2010 Apr; 58(2):179-83. PubMed ID: 19864084
[TBL] [Abstract][Full Text] [Related]
5. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology.
Geraets DT; Heideman DA; de Koning MN; Snijders PJ; van Alewijk DC; Meijer CJ; van Doorn LJ; Quint WG
J Clin Virol; 2009 Nov; 46 Suppl 3():S21-6. PubMed ID: 20129070
[TBL] [Abstract][Full Text] [Related]
6. Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes.
Seme K; Lepej SZ; Lunar MM; Iscić-Bes J; Planinić A; Kocjan BJ; Vince A; Poljak M
J Clin Virol; 2009 Oct; 46(2):176-9. PubMed ID: 19683958
[TBL] [Abstract][Full Text] [Related]
7. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
[TBL] [Abstract][Full Text] [Related]
9. Clinical Evaluation of INNO-LiPA HPV Genotyping
Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
[TBL] [Abstract][Full Text] [Related]
10. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
11. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Swede score colposcopy scoring system and histopathological results in patients with high-risk HPV infection other than HPV16 and 18.
Alan M; Gunyeli I; Gultekin M; Sancı M; Yuce K
Int J Gynecol Cancer; 2020 Jan; 30(1):35-40. PubMed ID: 31792083
[TBL] [Abstract][Full Text] [Related]
13. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results.
Mo LZ; Monnier-Benoit S; Kantelip B; Petitjean A; Riethmuller D; Prétet JL; Mougin C
J Clin Virol; 2008 Feb; 41(2):104-10. PubMed ID: 18036888
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens.
Kocjan BJ; Seme K; Poljak M
J Virol Methods; 2011 Jul; 175(1):117-9. PubMed ID: 21513740
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.
Stevens MP; Garland SM; Rudland E; Tan J; Quinn MA; Tabrizi SN
J Clin Microbiol; 2007 Jul; 45(7):2130-7. PubMed ID: 17494721
[TBL] [Abstract][Full Text] [Related]
17. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay.
Wong AK; Chan RC; Nichols WS; Bose S
J Clin Microbiol; 2008 Mar; 46(3):869-75. PubMed ID: 18174309
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cervical cancer in women with ASCUS in the Brazilian Unified National Health System: cost-effectiveness of the molecular biology method for HPV detection.
Nomelini RS; Guimarães PD; Candido PA; Campos AC; Michelin MA; Murta EF
Cad Saude Publica; 2012 Nov; 28(11):2043-52. PubMed ID: 23147946
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall.
Chiappetta C; Puggioni C; Lendaro E; Cacciotti J; Zaralli R; Migliore G; Bellardini P; Petrozza V; Della Rocca C; Di Cristofano C
Int J Clin Exp Pathol; 2015; 8(12):16089-96. PubMed ID: 26884886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
